Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775761 · ClinicalTrials.gov registry record · Phase 1
A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)
A Phase 1 study of TTR Cardiomyopathy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT01775761 is a Phase 1 study of TTR Cardiomyopathy that has completed, run by Pfizer. The registered enrollment target is 42 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01775761, a Phase 1 study of TTR Cardiomyopathy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to investigate the effects of tafamidis on the intervals of the electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers.
Conditions Studied
Interventions
- DRUG Period 1
- DRUG Period 2
- DRUG Period 3
Study Locations (3)
Connecticut
- Pfizer Investigational Site - New Haven
Other
- Pfizer Investigational Site - Brussels
Singapore
- Pfizer Investigational Site - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775761
The ClinicalTrials.gov registry entry for NCT01775761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with TTR Cardiomyopathy appearing as the primary indexed condition, and to 3 interventions - of which Period 1 is the first listed.
NCT01775761 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Other, Singapore.
Frequently Asked Questions
What is clinical trial NCT01775761 about?
NCT01775761 is a clinical study titled "A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)". The purpose of this study is to investigate the effects of tafamidis on the intervals of the electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers.
What is the current status of trial NCT01775761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2013-01. Estimated completion is 2013-04.
What conditions does trial NCT01775761 study?
This clinical trial studies the following conditions: TTR Cardiomyopathy.
What interventions are being tested in trial NCT01775761?
The interventions under investigation include: Period 1 (DRUG), Period 2 (DRUG), Period 3 (DRUG).
Who is sponsoring clinical trial NCT01775761?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01775761 being conducted?
This trial has 3 study locations across Connecticut, Singapore. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.